IMVT vs. SLNO, VTRS, ASND, QGEN, BPMC, BBIO, VRNA, ROIV, ELAN, and RVMD
Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), Viatris (VTRS), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector.
Immunovant vs. Its Competitors
Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.
Immunovant presently has a consensus price target of $36.30, indicating a potential upside of 107.55%. Soleno Therapeutics has a consensus price target of $108.70, indicating a potential upside of 30.04%. Given Immunovant's higher probable upside, equities research analysts clearly believe Immunovant is more favorable than Soleno Therapeutics.
47.1% of Immunovant shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Soleno Therapeutics had 5 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Soleno Therapeutics and 12 mentions for Immunovant. Immunovant's average media sentiment score of 0.88 beat Soleno Therapeutics' score of 0.83 indicating that Immunovant is being referred to more favorably in the media.
Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.
Immunovant has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.63, meaning that its stock price is 363% less volatile than the S&P 500.
Soleno Therapeutics' return on equity of -77.52% beat Immunovant's return on equity.
Summary
Soleno Therapeutics beats Immunovant on 8 of the 13 factors compared between the two stocks.
Get Immunovant News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunovant Competitors List
Related Companies and Tools
This page (NASDAQ:IMVT) was last updated on 7/15/2025 by MarketBeat.com Staff
Free IMVT Stock Alerts